{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:19:25Z","timestamp":1791332365598,"version":"4.3.1"},"reference-count":110,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Follicular lymphoma (FL) is a B-cell tumor arising in germinal centers and retaining features of its normal B-cell counterpart. Lymphomagenesis appears stepwise from the t(14;18) translocation, through FL-like cells, to FL in situ, then to overt FL. Surface Ig is mandatory and carries a striking V-region modification because of introduction of glycan addition sites during somatic mutation. These are positively selected and acquire unusual high mannoses, which interact with lectins. The Ig-associated mannoses appear essential for FL, providing a disease- specific target for antibody attack. Antibody therapy is currently focused on anti-CD20 (rituximab), which appears to rely predominantly on the Fc\u03b3 module recruiting suitably activated macrophages. Immunogloblulin and, to some extent, CD20, can each escape antibody attack in vitro by modulation, but this is difficult to demonstrate clinically. Instead, studies of anti-CD20 therapy of FL suggest that effector modulation, similar to that seen in the suppression of autoimmune inflammation by infusions of normal human IgG, may be important. Both antigenic and effector modulations might be minimized by repeated small doses of more potent antibodies. Clearly, mechanisms of attack vary with the malignancy, the target molecule, and the antibody design, offering opportunities for optimizing this promising strategy.<\/jats:p>","DOI":"10.1182\/blood-2011-11-367730","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T03:16:08Z","timestamp":1329362168000},"page":"3659-3667","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Follicular lymphoma and the immune system: from pathogenesis to antibody therapy"],"prefix":"10.1182","volume":"119","author":[{"given":"Freda K.","family":"Stevenson","sequence":"first","affiliation":[{"name":"Molecular Immunology Group, Cancer Sciences Academic Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Molecular Immunology Group, Cancer Sciences Academic Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"40","key":"2019111807331980200_B1","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1038\/sj.onc.1204640","article-title":"Mechanisms of chromosomal translocations in B cell lymphomas.","volume":"20","author":"Kuppers","year":"2001","journal-title":"Oncogene"},{"key":"2019111807331980200_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-385991-4.00001-5","article-title":"Early steps of follicular lymphoma pathogenesis.","volume":"111","author":"Roulland","year":"2011","journal-title":"Adv Immunol"},{"issue":"11","key":"2019111807331980200_B3","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1182\/blood-2011-05-355255","article-title":"Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma.","volume":"118","author":"Jegalian","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111807331980200_B4","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood-2007-11-124560","article-title":"S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells.","volume":"112","author":"Ruminy","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111807331980200_B5","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111807331980200_B6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","article-title":"Transformation of follicular lymphoma.","volume":"24","author":"Lossos","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"14","key":"2019111807331980200_B7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas.","volume":"29","author":"Montoto","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7360","key":"2019111807331980200_B8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"6","key":"2019111807331980200_B9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0092-8674(00)80373-6","article-title":"In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.","volume":"90","author":"Lam","year":"1997","journal-title":"Cell"},{"issue":"6","key":"2019111807331980200_B10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349","article-title":"A clinical trial of anti-idiotype therapy for B cell malignancy.","volume":"65","author":"Meeker","year":"1985","journal-title":"Blood"},{"issue":"7","key":"2019111807331980200_B11","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood.V99.7.2562","article-title":"Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma.","volume":"99","author":"Zhu","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2019111807331980200_B12","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1074\/jbc.M602690200","article-title":"Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.","volume":"282","author":"Radcliffe","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111807331980200_B13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4049\/jimmunol.130.2.970","article-title":"Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation.","volume":"130","author":"Stevenson","year":"1983","journal-title":"J Immunol"},{"issue":"17","key":"2019111807331980200_B14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111807331980200_B15","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"issue":"20","key":"2019111807331980200_B16","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111807331980200_B17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2019111807331980200_B18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807331980200_B19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood.V83.4.899.899","article-title":"Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein.","volume":"83","author":"Vuist","year":"1994","journal-title":"Blood"},{"issue":"2","key":"2019111807331980200_B20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action.","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"2","key":"2019111807331980200_B21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","article-title":"CD20 as a target for therapeutic type I and II monoclonal antibodies.","volume":"47","author":"Beers","year":"2010","journal-title":"Semin Hematol"},{"key":"2019111807331980200_B22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.immunol.16.1.421","article-title":"Divergent roles for Fc receptors and complement in vivo.","volume":"16","author":"Ravetch","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"12","key":"2019111807331980200_B23","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1172\/JCI16577","article-title":"C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease.","volume":"110","author":"Shushakova","year":"2002","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111807331980200_B24","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"issue":"20","key":"2019111807331980200_B25","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1182\/blood-2009-06-225839","article-title":"Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.","volume":"114","author":"Mottok","year":"2009","journal-title":"Blood"},{"issue":"15","key":"2019111807331980200_B26","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2008-08-174839","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone.","volume":"113","author":"Carlotti","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111807331980200_B27","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/sj.leu.2403841","article-title":"Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas.","volume":"19","author":"Schmitz","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"2019111807331980200_B28","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood.V95.9.2922.009k38_2922_2929","article-title":"Variable heavy chain gene analysis of follicular lymphomas: correlation between heavy chain isotype expression and somatic mutation load.","volume":"95","author":"Aarts","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2019111807331980200_B29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.2003.04064.x","article-title":"Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma.","volume":"120","author":"Zhu","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111807331980200_B30","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.molimm.2007.10.009","article-title":"Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma.","volume":"45","author":"McCann","year":"2008","journal-title":"Mol Immunol"},{"issue":"43","key":"2019111807331980200_B31","doi-asserted-by":"crossref","first-page":"18587","DOI":"10.1073\/pnas.1009388107","article-title":"Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins.","volume":"107","author":"Coelho","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2019111807331980200_B32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nri2417","article-title":"Mammalian glycosylation in immunity.","volume":"8","author":"Marth","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2019111807331980200_B33","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/ni.1903","article-title":"N-linked glycosylation selectively regulates autonomous precursor BCR function.","volume":"11","author":"Ubelhart","year":"2010","journal-title":"Nat Immunol"},{"key":"2019111807331980200_B34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.immunol.15.1.481","article-title":"CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.","volume":"15","author":"Tedder","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"29","key":"2019111807331980200_B35","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1073\/pnas.1002057107","article-title":"B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.","volume":"107","author":"Irish","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111807331980200_B36","doi-asserted-by":"crossref","first-page":"547179","DOI":"10.1155\/2010\/547179","article-title":"Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages.","volume":"2010","author":"Allavena","year":"2010","journal-title":"Clin Dev Immunol"},{"issue":"9","key":"2019111807331980200_B37","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2008-02-138933","article-title":"IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.","volume":"112","author":"Calvo","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111807331980200_B38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111807331980200_B39","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma.","volume":"28","author":"Relander","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111807331980200_B40","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111807331980200_B41","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJM198506273122602","article-title":"Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.","volume":"312","author":"Meeker","year":"1985","journal-title":"N Engl J Med"},{"key":"2019111807331980200_B42","first-page":"193","article-title":"Identification of human idiotype-specific T cells in lymphoma and myeloma.","volume":"344","author":"Weng","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"2019111807331980200_B43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4049\/jimmunol.138.2.628","article-title":"Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.","volume":"138","author":"George","year":"1987","journal-title":"J Immunol"},{"issue":"23","key":"2019111807331980200_B44","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1200\/JCO.2004.06.003","article-title":"Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.","volume":"22","author":"Weng","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111807331980200_B45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2172-3-16","article-title":"Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.","volume":"3","author":"Hsueh","year":"2002","journal-title":"BMC Immunol"},{"issue":"1","key":"2019111807331980200_B46","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-065X.2010.00937.x","article-title":"T cells and follicular dendritic cells in germinal center B-cell formation and selection.","volume":"237","author":"Vinuesa","year":"2010","journal-title":"Immunol Rev"},{"issue":"3","key":"2019111807331980200_B47","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood-2011-01-328864","article-title":"High-affinity memory B cells induced by conjugate vaccines against weak tumor antigens are vulnerable to nonconjugated antigen.","volume":"118","author":"Savelyeva","year":"2011","journal-title":"Blood"},{"issue":"6059","key":"2019111807331980200_B48","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.","volume":"334","author":"Pejchal","year":"2011","journal-title":"Science"},{"issue":"131","key":"2019111807331980200_B49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/newbio244022a0","article-title":"New look at antiserum therapy of leukaemia.","volume":"244","author":"Hersey","year":"1973","journal-title":"Nat New Biol"},{"issue":"1","key":"2019111807331980200_B50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/1074-7613(95)90155-8","article-title":"Cytotoxic antibodies trigger inflammation through Fc receptors.","volume":"3","author":"Clynes","year":"1995","journal-title":"Immunity"},{"issue":"4","key":"2019111807331980200_B51","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"6","key":"2019111807331980200_B52","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2004-01-0331","article-title":"FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways.","volume":"104","author":"Angelini","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111807331980200_B53","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"3","key":"2019111807331980200_B54","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1084\/jem.20052283","article-title":"Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.","volume":"203","author":"Hamaguchi","year":"2006","journal-title":"J Exp Med"},{"issue":"7","key":"2019111807331980200_B55","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.4049\/jimmunol.174.7.4389","article-title":"The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.","volume":"174","author":"Hamaguchi","year":"2005","journal-title":"J Immunol"},{"issue":"2","key":"2019111807331980200_B56","first-page":"166","article-title":"Tumor infiltrating cells in human cancer: on the possible role of CD16+ macrophages in antitumor cytotoxicity.","volume":"67","author":"van Ravenswaay Claasen","year":"1992","journal-title":"Lab Invest"},{"issue":"15","key":"2019111807331980200_B57","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1158\/0008-5472.CAN-10-4222","article-title":"Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.","volume":"71","author":"Hubert","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"2019111807331980200_B58","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"21","key":"2019111807331980200_B59","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807331980200_B60","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2019111807331980200_B61","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2007-02-074716","article-title":"NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"2019111807331980200_B62","first-page":"977","article-title":"Antigenic properties of experimental leukemias: I. Serological studies in vitro with spontaneous and radiation-induced leukemias.","volume":"31","author":"Old","year":"1963","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2019111807331980200_B63","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.140.4.939","article-title":"Antigenic modulation in vitro: I. Fate of thymus-leukemia (TL) antigen-antibody complexes following modulation of TL antigenicity from the surfaces of mouse leukemia cells and thymocytes.","volume":"140","author":"Stackpole","year":"1974","journal-title":"J Exp Med"},{"issue":"5729","key":"2019111807331980200_B64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/281305a0","article-title":"Cross-linking of lymphocytic surface immunoglobulin inhibits its production via a cyclic nucleotide mechanism.","volume":"281","author":"Glennie","year":"1979","journal-title":"Nature"},{"issue":"9","key":"2019111807331980200_B65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ni0903-815","article-title":"What is trogocytosis and what is its purpose?","volume":"4","author":"Joly","year":"2003","journal-title":"Nat Immunol"},{"issue":"4","key":"2019111807331980200_B66","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.","volume":"176","author":"Beum","year":"2006","journal-title":"J Immunol"},{"issue":"4","key":"2019111807331980200_B67","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-3083.2007.01996.x","article-title":"Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter by CD8(+) T cells.","volume":"66","author":"Riond","year":"2007","journal-title":"Scand J Immunol"},{"issue":"4","key":"2019111807331980200_B68","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.4049\/jimmunol.1002917","article-title":"Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.","volume":"186","author":"Zhou","year":"2011","journal-title":"J Immunol"},{"issue":"1","key":"2019111807331980200_B69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.143.1.15","article-title":"Calcium-sensitive modulation of Ig capping: evidence supporting a cytoplasmic control of ligand receptor complexes.","volume":"143","author":"Schreiner","year":"1976","journal-title":"J Exp Med"},{"issue":"1","key":"2019111807331980200_B70","first-page":"7","article-title":"Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis: I. Characterization with syngeneic and xenogeneic complements.","volume":"42","author":"Gordon","year":"1981","journal-title":"Immunology"},{"issue":"7","key":"2019111807331980200_B71","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4049\/jimmunol.146.7.2461","article-title":"Enhanced modulation of antibodies coating guinea pig leukemic cells in vitro and in vivo: the role of Fc gamma R expressing cells.","volume":"146","author":"Lane","year":"1991","journal-title":"J Immunol"},{"issue":"5851","key":"2019111807331980200_B72","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/295712a0","article-title":"Univalent antibodies kill tumour cells in vitro and in vivo.","volume":"295","author":"Glennie","year":"1982","journal-title":"Nature"},{"issue":"9","key":"2019111807331980200_B73","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111807331980200_B74","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V92.4.1184","article-title":"Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.","volume":"92","author":"Davis","year":"1998","journal-title":"Blood"},{"issue":"17","key":"2019111807331980200_B75","first-page":"4906","article-title":"Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.","volume":"49","author":"Press","year":"1989","journal-title":"Cancer Res"},{"issue":"10","key":"2019111807331980200_B76","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111807331980200_B77","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"2019111807331980200_B78","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.seminhematol.2010.01.006","article-title":"Antigenic modulation and rituximab resistance.","volume":"47","author":"Taylor","year":"2010","journal-title":"Semin Hematol"},{"issue":"10","key":"2019111807331980200_B79","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111807331980200_B80","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111807331980200_B81","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111807331980200_B82","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1073\/pnas.97.1.309","article-title":"The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma.","volume":"97","author":"Callanan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"52","key":"2019111807331980200_B83","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/sj.onc.1204989","article-title":"Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas.","volume":"20","author":"Chen","year":"2001","journal-title":"Oncogene"},{"issue":"16","key":"2019111807331980200_B84","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab.","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111807331980200_B85","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111807331980200_B86","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.100.2.376","article-title":"Relationship between molecular size and intra- and extravascular distribution of protein antigens.","volume":"100","author":"Nakamura","year":"1968","journal-title":"J Immunol"},{"issue":"8232","key":"2019111807331980200_B87","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"2019111807331980200_B88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":"Intravenous immunoglobulins: understanding properties and mechanisms.","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2019111807331980200_B89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-065X.2010.00910.x","article-title":"Antibody-mediated modulation of immune responses.","volume":"236","author":"Nimmerjahn","year":"2010","journal-title":"Immunol Rev"},{"issue":"7354","key":"2019111807331980200_B90","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2019111807331980200_B91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2006.11.010","article-title":"FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin.","volume":"26","author":"Park-Min","year":"2007","journal-title":"Immunity"},{"issue":"9","key":"2019111807331980200_B92","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.molimm.2007.12.020","article-title":"Monomerization of dimeric IgG of intravenous immunoglobulin (IVIg) increases the antibody reactivity against intracellular antigens.","volume":"45","author":"Wymann","year":"2008","journal-title":"Mol Immunol"},{"issue":"4","key":"2019111807331980200_B93","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V98.4.1095","article-title":"Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.","volume":"98","author":"Teeling","year":"2001","journal-title":"Blood"},{"key":"2019111807331980200_B94","first-page":"57","article-title":"Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia.","volume":"3","author":"Cheung","year":"2009","journal-title":"Biologics"},{"issue":"4","key":"2019111807331980200_B95","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2004.04804.x","article-title":"Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms.","volume":"124","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111807331980200_B96","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2004-05-1886","article-title":"Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg.","volume":"105","author":"Song","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111807331980200_B97","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.leukres.2004.08.001","article-title":"Is antibody therapy of tumor compromised by infusion-related reactions? A case for inhibiting the activity of cyclooxygenase-2.","volume":"29","author":"Stevenson","year":"2005","journal-title":"Leuk Res"},{"issue":"5503","key":"2019111807331980200_B98","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"issue":"11","key":"2019111807331980200_B99","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2010-07-298356","article-title":"The future of anti-CD20 monoclonal antibodies: are we making progress?","volume":"117","author":"Alduaij","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111807331980200_B100","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"issue":"24","key":"2019111807331980200_B101","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2019111807331980200_B102","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111807331980200_B103","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function.","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2019111807331980200_B104","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1158\/0008-5472.CAN-07-0696","article-title":"Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.","volume":"67","author":"Stavenhagen","year":"2007","journal-title":"Cancer Res"},{"issue":"30","key":"2019111807331980200_B105","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.","volume":"277","author":"Shields","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111807331980200_B106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(00)00338-0","article-title":"Introduction: bispecific antibodies.","volume":"248","author":"Segal","year":"2001","journal-title":"J Immunol Methods"},{"issue":"6793","key":"2019111807331980200_B107","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/35018508","article-title":"The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.","volume":"406","author":"Sondermann","year":"2000","journal-title":"Nature"},{"issue":"5","key":"2019111807331980200_B108","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.molimm.2010.11.019","article-title":"A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcgamma receptors II and III.","volume":"48","author":"Leong","year":"2011","journal-title":"Mol Immunol"},{"issue":"6504","key":"2019111807331980200_B109","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/372379a0","article-title":"Crystal structure of the complex of rat neonatal Fc receptor with Fc.","volume":"372","author":"Burmeister","year":"1994","journal-title":"Nature"},{"issue":"8","key":"2019111807331980200_B110","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","article-title":"Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.","volume":"164","author":"Idusogie","year":"2000","journal-title":"J Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/16\/3659\/1476135\/zh801612003659.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/16\/3659\/1476135\/zh801612003659.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T19:02:15Z","timestamp":1686769335000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/16\/3659\/29922\/Follicular-lymphoma-and-the-immune-system-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":110,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,4,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-367730","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}